- This is an open-label, single arm, phase II study of zidovudine (AZT) and Belinostat, as consolidation therapy with optional interferon-alfa-2b (IFN-alfa-2b) or pegylated interferon-alfa-2b (PEG-IFN-alfa-2b). For subjects receiving interferon therapy at baseline, the corresponding interferon, IFN-alfa-2b at 5 million IU daily or PEG-IFN-alfa-2b at 1.5 μg/kg once weekly, may be continued. Subjects will receive up to 8 cycles of Belinostat combined with AZT (as consolidation) followed by AZT-based maintenance therapy (± IFN-alfa) for at least 6 more months.